Listing & Compliance Notices

Freight Technologies, Inc. received a nasdaq deficiency notice notice regarding stockholders equity.

“January 13, 2024, Freight Technologies, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Capital Market (“Nasdaq”) notifying the Company that, since the Company’s Form 8-K filed January 10, 2025, disclosed stockholders’ equity of ($32,356), as of June 30, 2024, and as of now, the Company does not meet the alternatives of market value of listed securities or net income from continuing operations, the Company no longer complies with Nasdaq listing rules (the “Rules”) requiring companies listed on the Nasdaq Ca”

Beneficient received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 13, 2025, Beneficient (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the closing bid price for the Company’s Class A common stock, par value $0.001 per share (the “Class A Common Stock”), had been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The Notice has no effect at this time on the Class A Comm”

CISO Global, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 10, 2025, CISO Global Inc. (the “Company”) received a notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, since the Company has not yet held an annual meeting of shareholders within twelve months of the end of its December 31, 2023 fiscal year, it is out of compliance with the Nasdaq rules for continued listing (Listing Rules 5620(a) and 5810(c)(2)(G)). The notification letter has no immediate effect on the listing of the Company’s securities on the Nasdaq Capital Market. Under the applicable Nasdaq rules, the Company now”

Papaya Growth Opportunity Corp. I received a nasdaq delisting notice notice regarding other (rules IM-5101-2).

“January 16, 2025, the Company received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) that the Company’s securities will be delisted from The Nasda”

CISO Global, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 10, 2025, CISO Global Inc. (the “Company”) received a notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, since the Company has not yet held an ann”

Beneficient received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 13, 2025, Beneficient (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previo”

Freight Technologies, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)).

“January 13, 2024, Freight Technologies, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Capital Market (“Nasdaq”) notifying the Comp”

Sports Entertainment Gaming Global Corp received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a)).

“January 10, 2025, Lottery.com Inc. (the “Company” or the “Registrant”) received a written notice (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that th”

AQUABOUNTY TECHNOLOGIES INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“imum bid price requirement for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Notice has no immediate effect on the Company’s listing”

VivoSim Labs, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 16, 2025, the Staff provided a notice to the Company (the “Nasdaq Notice”) that the Company had not regained compliance with Rule 5550(a)(2) and is not eligible for a second 180 calendar day compliance period as”

Viracta Therapeutics, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2), 5605(c)(4)).

“January 13, 2025, Viracta Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of”

Protagenic Therapeutics, Inc.new received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 15, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications department (“Nasdaq”) regarding the timing of its annual meeting of shareholders. Nasdaq noted that the Company has not yet held an annual meeting of shareholders within twelve months of the end of its December 31, 2023 fiscal year, as required under Listing Rules 5620(a) and 5810(c)(2)(G). The Company has already scheduled its annual meeting to occur no later than February 21, 2025, and is committed to addressing this compliance matter. This notification is par”

INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5801(s)(2)(G)).

“January 10, 2025, the Company received notice (the “Notice”) from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it no longer complies with Nasdaq Listing Rules 5620(a) and 5801(s)(2)(G) that require companies listed on The Nasdaq Capital Market to hold an annual meeting of shareholders (an “ASM”) within twelve months of the fiscal year’s end (the “ASM Rule”). The Company did not hold an ASM in its fiscal year ended December 31, 2024. The Notice has no immediate effect on the listing of the Company’s common stock and the Company’s common stock conti”

REALLOYS INC. received a nasdaq deficiency notice notice regarding board independence (rules 5605(b)(1), 5605(c)(2)(A), 5605(b)(1)(A), 5605(c)(4)).

“January 13, 2025, the Company received a notice (the “Annual Meeting Notice”) from the Listing Qualifications Department of Nasdaq stating that, consistent with Nasdaq Listing Rule 5810(c)(2)(G), the Company has 45 calendar days from the date of the Annual Meeting Notice ( i.e. , February 27, 2025) to submit a plan to regain compliance, and if Nasdaq accepts such plan, Nasdaq can grant an exception of up to 180 calendar days from the fiscal year end ( i.e. , June 30, 2025) to regain compliance. The Company has scheduled its 2024 annual meeting of the stockholders for February 7, 2025 in order”

REALLOYS INC. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 13, 2025, the Company received a notice (the “Annual Meeting Notice”) from the Listing Qualifications Department of Nasdaq stating that, consistent with Nasdaq Listing Rule 5810(c)(2)(G), the Company has 45 calendar days from the date of the Annual Meeting Notice ( i.e. , February 27, 2025) to submit a plan to regain compliance, and if Nasdaq accepts such plan, Nasdaq can grant an exception of up to 180 calendar days from the fiscal year end ( i.e. , June 30, 2025) to regain compliance. The Company has scheduled its 2024 annual meeting of the stockholders for February 7, 2025 in order”

RideNow Group, Inc. received a nasdaq noncompliance notice notice regarding board independence (rules 5605(b)(1)).

“January 14, 2025, RumbleOn, Inc. (the “Company”) notified the Nasdaq Stock Market, LLC (“Nasdaq”) that the Company is temporarily not in compliance with continued listing requirements as set forth in Nasdaq Listing Rules 5605(b)(1) regarding the composition of the board of directors of the Company (the “Board”) because a majority of the Board is not comprised of Independent Directors (as defined in Nasdaq Listing Rule 5605(a)(2)) solely due to a vacancy on the Board resulting from the leadership transition described in”

Hall of Fame Resort & Entertainment Co received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

“January 10, 2025, Hall of Fame Resort & Entertainment Company (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) stating that the Company failed to hold an annual meeting of stockholders within 12 months after its fiscal year ended December 31, 2023, as required by Nasdaq Listing Rule 5620(a) (the “Annual Meeting Requirement”). The Notice has no immediate impact on the listing of the Company’s common stock (the “Common Stock”) on Nasdaq. Under Nasdaq Rules, the Company has 45 calendar d”

Momentus Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)).

“January 13, 2025, Momentus Inc., a Delaware corporation (the “Company”), received a letter issued by Nasdaq Hearings Panel (the “Panel”) granting the Company’s request to continue its listing on The Nasdaq Capital Market (“Nasdaq”) until April 15, 2025 while the Company executes its plan to regain compliance with the requirements of Nasdaq Listing Rule 5550(b). Additionally, the Panel confirmed that the Company has regained compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2), as a r”

Momentus Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“January 13, 2025, Momentus Inc., a Delaware corporation (the “Company”), received a letter issued by Nasdaq Hearings Panel (the “Panel”) granting the Company’s request to continue its listing on The Nasdaq Capital Market (“Nasdaq”) until April 15, 2025 while the Company executes its plan to regain compliance with the requirements of Nasdaq Listing Rule 5550(b). Additionally, the Panel confirmed that the Company has regained compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2), as a r”

Leafly Holdings, Inc. /DE received a nasdaq delisting notice notice regarding other (rules 5550(b)).

“ation from the Listing Qualifications Staff of Nasdaq notifying the Company that it no longer complied with the minimum $500,000 in net income from continuing operations in the most recently completed fiscal year, or two of the last three fiscal years for continued listing set forth in Listing Rule 5550(b) or any of Nasdaq's alternative continued listing requirements contained in Nasdaq Listing Rule 5550 for companies traded on the Nasdaq Capital Market (the “Continued Listing Standards”). In connection with the Panel’s decision, Nasdaq will file a Form 25 with the Securities and Exchange Comm”

CSLM ACQUISITION CORP. received a nasdaq delisting notice notice regarding other (rules IM-5101-2).

“January 15, 2025 CSLM Acquisition Corp. (the “ Company ”) received a notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”), stating that the Company did not comply with Nasdaq Interpretive Material IM-5101-2, and that its securities are now subject to delisting. The Company’s registration statement, filed in connection with the Company’s IPO, became effective January 12, 2022. Pursuant to IM-5101-2, the Company, a special purpose acquisition company, must complete one or more business combinations within 36 months of the effectiveness of its IPO registration statement. Since th”

CSLM ACQUISITION CORP. received a nasdaq delisting notice notice regarding other (rules IM-5101-2).

“January 15, 2025 CSLM Acquisition Corp. (the “ Company ”) received a notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”), stating that the Company did not comply with Nasdaq Interpretive Material IM-510”

Leafly Holdings, Inc. /DE received a nasdaq delisting notice notice regarding other (rules 5550(b)).

“January 15, 2025, the Company received written notification (the “Delisting Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s common”

Momentus Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)).

“January 13, 2025, Momentus Inc., a Delaware corporation (the “Company”), received a letter issued by Nasdaq Hearings Panel (the “Panel”) granting the Company’s request to continue its listing on The Nasdaq Capital Marke”

Momentus Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“January 13, 2025, Momentus Inc., a Delaware corporation (the “Company”), received a letter issued by Nasdaq Hearings Panel (the “Panel”) granting the Company’s request to continue its listing on The Nasdaq Capital Marke”

Hall of Fame Resort & Entertainment Co received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a)).

“January 10, 2025, Hall of Fame Resort & Entertainment Company (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq””

RideNow Group, Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605(b)(1)).

“January 14, 2025, RumbleOn, Inc. (the “Company”) notified the Nasdaq Stock Market, LLC (“Nasdaq”) that the Company is temporarily not in compliance with continued listing requirements as set forth in Nasdaq Listing Rules”

INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5801(s)(2)(G)).

“January 10, 2025, the Company received notice (the “Notice”) from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it no longer complies with Nasdaq Listing Rules 5620(a) and 58”

Protagenic Therapeutics, Inc.new received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 15, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications department (“Nasdaq”) regarding the timing of its annual meeting of shareholders. Nasd”

BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

“January 15, 2025, the Company received written notice from the Staff of Nasdaq notifying it that the Company failed to regain compliance with the MVLS Requirement by the Compliance Date. As such, unless the Company requests an appeal of Nasdaq’s determination to delist the Company’s common stock from The Nasdaq Capital Market by January 22, 2025, the Company’s common stock will be delisted from The Nasdaq Capital Market at the opening of business on January 24, 2025. While the Company intends to appeal Nasdaq’s decision, no guarantee can be provided that it will be successful in doing so and t”

SPI Energy Co., Ltd. received a nasdaq delisting notice notice regarding other (rules 5250(c)(1), 5550(a)(2)).

“January 13, 2025, SPI Energy Co., Ltd., a Cayman Islands company (the “Company”), received a notification letter (the “Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Nasdaq hearings panel had determined to delist the Company’s shares from The Nasdaq Capital Market, due to the Company’s violation of Listing Rules 5250(c)(1) and 5550(a)(2), the “Bid Price Requirement” and “Annual Shareholder Meeting” Rules. The Letter stated that the Hearing Panel has determined to delist the Company’s shares from Nasdaq and trading in the Company’s securities will be suspend”

Hepion Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding shareholders.

“January 14, 2025, Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), received written notice (the “ Notice ”) from the Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that since the Company had not held an annual meeting of shareholders within twelve months of the Company’s fiscal year end (the “Listing Rule”), the Company no longer complies with the Listing Rule for continued listing. The Notice has no effect at this time on the Common Stock, which continues to trade on the Nasdaq Capital Market under the symbol “HEPA.” Under the Listing Rule, the Company has 45 days to”

Gain Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“f The Nasdaq Stock Market (“Nasdaq”) notifying the Company that that from November 14, 2024 to December 27, 2024, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $50 million required for continued listing on The Nasdaq Global Market, pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”). The MVLS Deficiency Notice had no immediate effect on the listing of the Company’s common stock, and the Company’s common stock continues to trade on the Nasdaq Global Market under the symbol “GANX.” As of January 14, 2025, the Company has regained compliance”

Ocean Biomedical, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 7, 2025, the Company received a notice from Nasdaq that since the Company had not yet held an annual meeting of shareholders within twelve months of the Company’s fiscal year ended December 31, 2023, it no longer complies with the Listing Rules (the “Rules”) for continued listing.( Listing Rules 5620(a) and 5810(c)(2)(G)). Accordingly, this matter serves as an additional basis for delisting the Company’s securities from The Nasdaq Stock Market. This is formal notification that the Nasdaq Hearings Panel (the “Panel”) will consider this matter in their decision regarding the Company’s co”

Stran & Company, Inc. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

“December 17, 2024, the Company received a letter from the Staff issuing a Staff delisting determination (the “Staff Determination”). The Staff Determination noted that the Staff had notified the Company on June 21, 2024, August 23, 2024, and November 21, 2024, that the Company did not comply with Nasdaq Listing Rule 5250(c)(1) (the “Filing Rule”) because the Company had not filed its Quarterly Reports on Forms 10-Q for the periods ended March 31, 2024, June 30, 2024, and September 30, 2024 (the “Forms 10-Q”), with the Securities and Exchange Commission (the “SEC”). The Staff Determination note”

Stran & Company, Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a)).

“January 10, 2025, Stran & Company, Inc., a Nevada corporation (the “Company”), received a letter from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), notifying it that since the Company has not yet held an annual meeting of stockholders within twelve months of the end of the Company’s fiscal year end, it no longer complies with Nasdaq Listing Rule 5620(a). Accordingly, this matter serves as an additional basis for delisting the Company’s securities from Nasdaq. The Staff indicated that the letter was formal notification that the Nasdaq Hearings Panel (”

LUXURBAN HOTELS INC. received a nasdaq delisting notice notice regarding other (rules 5250(c)(1), 5550(a)(2), 5555(a)).

“January 15, 2025, LuxUrban Hotels Inc. (the “Company”) received notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s securities from Nasdaq based upon the Company’s non-compliance with Listing Rule Listing Rules 5250(c)(1), 5550(a)(2) and 5555(a). As a result of the Panel’s decision, Nasdaq will suspend trading in the Company’s securities effective at the open of trading on Friday, January 17, 2025. The Company has 15 days after the date it received notice of the Panel’s decision to request that the Na”

CLEARONE INC received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 10, 2025, the Company received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) informing the Company that because the Company did not hold an annual meeting of stockholders in 2024, the Company is not in compliance with the requirement to conduct an annual meeting of stockholders no later than one year after the end of its fiscal year, as set forth in Nasdaq Marketplace Rule 5620(a) (the “Annual Meeting Requirement”). In accordance with Nasdaq Marketplace Rule 5810(c)(2)(G), the Company has a period of 45 calendar d”

CLEARONE INC received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 10, 2025, the Company received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) informing the Company that because the Company did not hold an”

LUXURBAN HOTELS INC. received a nasdaq delisting notice notice regarding other (rules 5250(c)(1), 5550(a)(2), 5555(a)).

“January 15, 2025, LuxUrban Hotels Inc. (the “Company”) received notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s securities”

Stran & Company, Inc. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

“December 17, 2024, the Company received a letter from the Staff issuing a Staff delisting determination (the “Staff Determination”). The Staff Determination noted that the Staff had notified the Company on June 21, 2024”

Stran & Company, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

“January 10, 2025, Stran & Company, Inc., a Nevada corporation (the “Company”), received a letter from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), notifying it that since the”

Ocean Biomedical, Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a), 5810(c)(2)(G)).

“January 7, 2025, the Company received a notice from Nasdaq that since the Company had not yet held an annual meeting of shareholders within twelve months of the Company’s fiscal year ended December 31, 2023, it no longer”

Gain Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“um of $50 million required for continued listing on The Nasdaq Global Market, pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”). The MVLS Deficiency Notice had no immediate effect on the listing of t”

Hepion Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding shareholders.

“January 14, 2025, Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), received written notice (the “ Notice ”) from the Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that since the Company had not”

BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

“January 15, 2025, the Company received written notice from the Staff of Nasdaq notifying it that the Company failed to regain compliance with the MVLS Requirement by the Compliance Date. As such, unless the Company reque”

CISO Global, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 10, 2025, CISO Global Inc. (the “Company”) received a notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, since the Company has not yet held an annual meeting of shareholders within twelve months of the end of its December 31, 2023 fiscal year, it is out of compliance with the Nasdaq rules for continued listing (Listing Rules 5620(a) and 5810(c)(2)(G)). The notification letter has no immediate effect on the listing of the Company’s securities on the Nasdaq Capital Market. Under the applicable Nasdaq rules, the Company now”

PHOENIX MOTOR INC. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a), 5810(c)(2)(G)).

“January 10, 2025, Phoenix Motor Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”), which stated that the Company no longer complies with Nasdaq’s continued listing rules due to the Company not having held an annual meeting of shareholders within twelve months of the end of the Company’s fiscal year end, as required pursuant to Nasdaq Listing Rule 5620(a). In accordance with Nasdaq Listing Rule 5810(c)(2)(G), the Company has 45 calendar days to submit a plan to regain compliance and, if Nasdaq accepts the plan, Nasdaq can grant the Company an exception of up to”

Nature's Miracle Holding Inc. received a nasdaq delisting notice notice regarding other (rules 5550(b)(1)).

“January 13, 2025, Nature’s Miracle Holding Inc. (the “Company”) received notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s securities from Nasdaq based upon the Company’s non-compliance with Listing Rule 5550(b)(1), Nasdaq’s minimum shareholders’ equity rule. As a result of the Panel’s decision, Nasdaq will suspend trading in the Company’s securities effective at the open of trading on Wednesday, January 15, 2025. The Company has 15 days after the date it received notice of the Panel’s decision to r”

ENZO BIOCHEM INC received a nyse noncompliance notice notice regarding minimum bid price (rules 802.01B, 802.01C).

“January 8, 2025 Enzo Biochem, Inc. (the “Company”) received a letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Manual because as of January 7, 2025, the Company’s 30 trading-day average market capitalization was less than $50 million and its last reported stockholder’s equity as of October 31, 2024 was less than $50 million and (ii) Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s Common Stock (the “Common Stock”) was less than $1.00 ove”